Lineage Cell Therapeutics Inc
F:BT3
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Lineage Cell Therapeutics Inc
F:BT3
|
US |
|
B
|
Brown-Forman Corp
SWB:BF5B
|
US |
|
Orange SA
BMV:ORANN
|
FR |
|
Linde India Ltd
BSE:523457
|
IN |
Lineage Cell Therapeutics Inc
Lineage Cell Therapeutics is a biotechnology company that develops cell-based medicines, with a focus on using living cells to replace or repair damaged tissue. Its main work is in regenerative medicine, especially programs for eye disease and spinal cord-related conditions. The company does not sell consumer products; it sells science, drug candidates, and development rights that could become future treatments. Its customers are not ordinary shoppers but larger drug developers, hospitals, and ultimately doctors and patients if a therapy is approved. Lineage can make money through research and development collaborations, licensing deals, milestone payments, and future product sales or royalties if its therapies reach the market. Most of its value comes from advancing cell therapy candidates through testing and partnering with bigger companies that can help fund later-stage development. What makes Lineage different is that it works in a part of biotech that uses actual living cells as the therapeutic product, not just chemicals or antibodies. That makes its business more like a specialized research platform than a traditional drug maker. The company’s role in the healthcare value chain is to create early cell therapy assets and move them far enough along for larger partners or the market to carry them forward.
Lineage Cell Therapeutics is a biotechnology company that develops cell-based medicines, with a focus on using living cells to replace or repair damaged tissue. Its main work is in regenerative medicine, especially programs for eye disease and spinal cord-related conditions. The company does not sell consumer products; it sells science, drug candidates, and development rights that could become future treatments.
Its customers are not ordinary shoppers but larger drug developers, hospitals, and ultimately doctors and patients if a therapy is approved. Lineage can make money through research and development collaborations, licensing deals, milestone payments, and future product sales or royalties if its therapies reach the market. Most of its value comes from advancing cell therapy candidates through testing and partnering with bigger companies that can help fund later-stage development.
What makes Lineage different is that it works in a part of biotech that uses actual living cells as the therapeutic product, not just chemicals or antibodies. That makes its business more like a specialized research platform than a traditional drug maker. The company’s role in the healthcare value chain is to create early cell therapy assets and move them far enough along for larger partners or the market to carry them forward.
OpRegen: Management said the lead dry AMD program continues to look promising, pointing to longer-lasting vision gains, 11 new clinical sites added by Genentech in late 2025, and the first use of language describing the program as potentially disease-modifying.
Pipeline: Lineage highlighted progress across several newer programs, including COR1 in corneal disease, ReSonance in hearing loss, and ILT1 for type 1 diabetes, all built around the AlloSCOPE manufacturing platform.
Manufacturing focus: The company repeatedly stressed that in cell therapy, the process is the product, and said it is building scalable manufacturing before moving deeper into clinical development.
Cash runway: Lineage ended the quarter with $53.4 million in cash, which it says should fund operations into Q2 of 2028.
Quarterly results: Revenue was $1.7 million and net loss attributable to Lineage was $4.8 million, versus $4.1 million a year earlier.
Partner value: Management said it remains eligible for up to $615 million in potential developmental and commercial milestone payments under the Roche/Genentech collaboration.
